Search results for " Drug"

showing 10 items of 3138 documents

Oxcarbazepine does not affect the anticoagulant activity of warfarin.

1992

The possible interaction of the antiepileptic drug oxcarbazepine (OCBZ) on the anticoagulant effect of warfarin was investigated in 10 healthy male volunteers. After reaching steady-state conditions by repeated administration of warfarin, the prothrombin time (Quick value) was assessed before and after single (600 mg) and multiple dosing (450 mg twice daily in 1 week) of OCBZ. In 7 of the 10 volunteers with evaluable data, the prothrombin time was not significantly different (paired t test) from baseline either after single (p = 0.299) or repeated dosing (p = 0.333), indicating that OCBZ does not interact to any relevant extent with the hypothrombinemic effect of warfarin.

DrugAdultMalemedicine.drug_classmedia_common.quotation_subjectmedicine.medical_treatmentOxcarbazepinePharmacologymedicineHumansDrug InteractionsOxcarbazepineBlood Coagulationmedia_commonProthrombin timeChemotherapymedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryAnticoagulantWarfarinDose–response relationshipAnticonvulsantCarbamazepineNeurologyAnesthesiaProthrombin TimeAnticonvulsantsNeurology (clinical)Warfarinbusinessmedicine.drugEpilepsia
researchProduct

Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources.

2006

Aims To compare information on drug–drug interactions (DDIs) reported on two standard drug-related information sources (Summary of Product Characteristics and Drugdex system by Micromedex), by assessing the prevalence and predictors of potential DDI with proton pump inhibitors (PPIs) in general practice. Methods From the ‘Caserta-1’ Local Health-Service database, 156 general practitioners (GPs) were recruited. From more than 180 000 individuals registered on their lists, we selected patients receiving co-prescription of PPI and medications at interaction risk, according to the Italian Summary of Product Characteristics (SPC) of PPI and Drugdex information, during the year 2003. Thereafter, …

DrugAdultMalemedicine.medical_specialtyAdolescentmedia_common.quotation_subjectPharmacology toxicologyToxicologyDrugdexDrug PrescriptionsInternal medicineEpidemiologymedicineHumansPharmacology (medical)Drug InteractionsSummary of Product CharacteristicsRisk factorMedical prescriptiondrug information sourcesSummary of Product Characteristicsmedia_commonAgedgeneral practicePharmacologyAged 80 and overObserver VariationDrug pairbusiness.industryPharmacoepidemiologydrug information sources Drugdex drug–drug interaction general practice proton pump inhibitors Summary of Product CharacteristicsRegression analysisProton Pump InhibitorsDrug interactionMiddle Ageddrug information sources; Drugdex; drug-drug interaction; general practice; proton pump inhibitors; Summary of Product CharacteristicsSpontaneous reportingFamily medicineDrug Information ServicesInformation sourceFemalebusinessFamily Practicedrug-drug interactionBritish journal of clinical pharmacology
researchProduct

Influence of concomitant medications on the total clearance and the risk for supra-therapeutic plasma concentrations of Citalopram. A population-base…

2014

Introduction: The main objective of this study was to investigate the influence of the use of multiple medications and other risk factors on citalopram plasma concentrations. Methods: A retrospective cohort study with a naturalistic population of 957 patients for whom routine therapeutic drug monitoring (TDM) of citalopram had been requested between 2006 and 2013 was conducted. Results: Concomitant drugs inhibiting at least 2 different CYP subtypes involved in the metabolism of citalopram decreased statistically significantly the total clearance (Clt). Compared to younger patients over 64-year-old patients had on average a 4.5 times higher risk rate of supra-therapeutic plasma concentration…

DrugAdultMalemedicine.medical_specialtyMetabolic Clearance Ratemedia_common.quotation_subjectPopulationPharmacologyCitalopramCitalopramLogistic regressionbehavioral disciplines and activitiesSex FactorsPharmacokineticsRisk FactorsInternal medicinemental disordersmedicineCytochrome P-450 Enzyme InhibitorsHumansPharmacology (medical)Body Weights and MeasuresDrug Interactionseducationmedia_commonAgedRetrospective StudiesCytochrome P-450 Enzyme Inducerseducation.field_of_studymedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryAge FactorsRetrospective cohort studyGeneral MedicineMiddle AgedPsychiatry and Mental healthTherapeutic drug monitoringConcomitantAntidepressive Agents Second-GenerationFemaleDrug MonitoringbusinessSelective Serotonin Reuptake Inhibitorsmedicine.drugPharmacopsychiatry
researchProduct

Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV geno…

2014

BackgroundPrevious trials have often defined genotype 2 and 3 patients as an "easy to treat" group and guidelines recommend similar management.AimsThe present study looks for differences between the two genotypes and analyzes predictive factors for SVR.MethodsProspective, community-based cohort study involving 421 physicians throughout Germany. The analysis includes 2,347 patients with untreated chronic HCV genotype 2 (n = 391) and 3 (n = 1,956) infection treated with PEG-IFN α-2a plus ribavirin between August 2007 and July 2012.ResultsWhen compared with genotype 2 patients, those with genotype 3 were younger, had a shorter duration of infection, lower values of total cholesterol, LDL chole…

DrugAdultMalemedicine.medical_specialtyMultivariate analysisGenotypeGastroenterology and hepatologyHepacivirusmedia_common.quotation_subjectScienceHepacivirusGastroenterologyCohort Studieschemistry.chemical_compoundInternal medicineGermanyAlcohols Cholesterol; Dose prediction methods; Drug therapy; Fibrosis; Multivariate analysis; Physicians; Treatment guidelinesGenotypemedicineHumansLiver diseasesmedia_commonMedicine and health sciencesMultidisciplinarybiologybusiness.industryRibavirinQRHepatitis CMiddle Agedbiology.organism_classificationmedicine.diseaseHepatitis C3. Good healthClinical trialInfectious hepatitischemistryImmunologyMedicineFemalebusinessCohort studyResearch ArticlePloS one
researchProduct

[Drugs use in pregnancy in the Valencia Region and the risk of congenital anomalies].

2017

Background Despite the potential risks of drug use during pregnancy, consumption has increased in recent decades. Objective To identify the risk of congenital anomalies (CA) associated with the use of drugs in primary care in pregnant women resident in the Valencia Region. Methods A case-control study, considering a case as a less than one year old live birth in 2009–2010, diagnosed with a CA and resident in the Valencia Region, obtained from the CA population-based registry. Controls were selected from the Metabolic Disease Registry, and the drugs prescribed and dispensed from the Integral Management of Pharmaceutical Services. Crude odds ratio (OR) was calculated with its 95% confidence i…

DrugAdultMalemedicine.medical_specialtyPreparación farmacéuticaEmbarazomedia_common.quotation_subjectPopulationLogistic regressionPediatricsRJ1-570Comunitat Valenciana03 medical and health sciencesYoung Adult0302 clinical medicinePregnancyRisk FactorsManagement of Technology and InnovationInternal medicineAmbulatory CareMedicineAnomalías congénitasHumans030212 general & internal medicineeducationmedia_commonPregnancyeducation.field_of_study030219 obstetrics & reproductive medicinebusiness.industryInfant NewbornAbnormalities Drug-InducedOdds ratioDexketoprofenmedicine.diseaseConfidence intervalSurgeryPregnancy ComplicationsSpainCase-Control StudiesFemalebusinessLive birthmedicine.drugFactores de riesgoAnales de pediatria (Barcelona, Spain : 2003)
researchProduct

Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey.

2009

INTRODUCTION The aim of this study was to relate drug concentrations in serum and clinical effects in patients treated with the new antidepressant duloxetine. METHODS Data were obtained from a newly established therapeutic drug monitoring (TDM) survey. Duloxetine was measured using HPLC with UV detection and clinical effects by the clinical global impressions (CGI) scale for improvement. RESULTS The study included 103 depressed inpatients (69% female). Patients under duloxetine monotherapy who were very much improved according to CGI had significantly (p<0.05) higher serum levels than patients with moderate, minimal or lacking improvement (mean+/-SD and range, 93+/-53 ng/mL and 30-182 ng/mL…

DrugAdultMalemedicine.medical_specialtyUltraviolet Raysmedia_common.quotation_subjectUrologyThiophenesPharmacologyDuloxetine HydrochlorideDuloxetine HydrochlorideSeverity of Illness Indexchemistry.chemical_compoundYoung AdultSeverity of illnessMedicineDuloxetineHumansPharmacology (medical)Chromatography High Pressure Liquidmedia_commonAgedAged 80 and overDepressive DisorderReceiver operating characteristicmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industrySpectrum AnalysisGeneral MedicineSerum concentrationMiddle AgedAntidepressive AgentsPsychiatry and Mental healthDose–response relationshipTreatment OutcomechemistryROC CurveTherapeutic drug monitoringFemaleDrug MonitoringbusinessPharmacopsychiatry
researchProduct

Prescription drug use during pregnancy in France: a study from the national health insurance permanent sample.

2017

International audience; PurposeTo provide an up-to-date account of drug prescription during pregnancy in France from 2011 to 2014 using the permanent sample of the French national computerized healthcare database and with a focus on recommended supplementations, fetotoxic drugs and teratogenic drugs.MethodsAll pregnancies identified by the International Classification of Diseases, 10th Revision codes list in the hospitalization database, lasting more than 9 weeks of amenorrhea and whose delivery occurred between 01/01/2011 and 12/31/2014, were included. Drugs delivered between the trimester before and until the end of the pregnancy were included. Drug exposure prevalence was calculated for …

DrugAdultPediatricsmedicine.medical_specialtypharmacoepidemiologyPrescription drugPrescription DrugsNational Health ProgramsEpidemiologymedia_common.quotation_subject[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics030226 pharmacology & pharmacy03 medical and health sciencesYoung Adult0302 clinical medicinePregnancymedicineHumansPharmacology (medical)Medical prescriptionPregnancy Trimestersmedia_commonPregnancy030219 obstetrics & reproductive medicinebusiness.industrydrug recommendationsadministrative healthcare databasePharmacoepidemiologymedicine.diseaseDrug classTeratogensprescription medicationsAmenorrheaFemaleFrancePregnancy Trimestersmedicine.symptombusinessPharmacoepidemiology and drug safety
researchProduct

Polymer-doxycycline conjugates as fibril disrupters: an approach towards the treatment of a rare amyloidotic disease.

2014

The term amyloidosis describes neurological diseases where an abnormal protein is misfolded and accumulated as deposits in organs and tissues, known as amyloid, disrupting their normal function. In the most common familial amyloid polyneuropathy (FAP), transthyretin (TTR) displays this role primarily affecting the peripheral nervous system (PNS). Advanced stages of this inherited rare amyloidosis, present as fibril deposits that are responsible for disease progression. In order to stop disease progression, herein we designed an efficient family of nanoconjugates as fibril disrupters. These polymer conjugates are based on doxycycline (doxy), already in phase II trials for Alzheimer's disease…

DrugAmyloidErythrocytesAmyloidmedia_common.quotation_subjectPharmaceutical ScienceMice TransgenicFibrilHemolysisPlasmaIn vivomedicinePolymeric drugAnimalsTissue DistributionAmyloid disruptersmedia_commonDoxycyclineAmyloid Neuropathies FamilialMice Inbred BALB CbiologyChemistryAmyloidosismedicine.diseaseRare diseasesRatsTransthyretinPolymer-drug conjugateDisease Models AnimalDrug LiberationBiochemistryPolyglutamic AcidDoxycyclineDrug deliveryDrug deliverybiology.proteinCancer researchPolymer therapeuticsmedicine.drugJournal of controlled release : official journal of the Controlled Release Society
researchProduct

Micellar electrokinetic capillary chromatography for therapeutic drug monitoring of carbamazepine and its main metabolites.

1998

In carbamazepine (CBZ) therapy the concomitant monitoring of concentrations of CBZ and its metabolites is strictly recommended, primarily to avoid toxic side effects. Currently, clinical routine monitoring of CBZ is accomplished by high-performance liquid chromatography or immunological methods. In this study a micellar electrokinetic capillary chromatographic (MECC) method was developed for routine drug monitoring of CBZ and its main metabolites, carbamazepine 10,11-diol and carbamazepine 10,11-epoxide, in human serum or plasma samples. The MECC method enabled baseline separation of all analytes within 2.5 min. The assay revealed sufficient precision and sensitivity and the results of eith…

DrugAnalyteChromatographymedicine.diagnostic_testChemistrymedia_common.quotation_subjectMetabolitemedicine.medical_treatmentElectrophoresis CapillaryGeneral ChemistryCarbamazepineHigh-performance liquid chromatographyMicellar electrokinetic chromatographychemistry.chemical_compoundAnticonvulsantCarbamazepineTherapeutic drug monitoringmedicineHumansAnticonvulsantsDrug MonitoringChromatography High Pressure Liquidmedia_commonmedicine.drugJournal of chromatography. B, Biomedical sciences and applications
researchProduct

Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).

2008

Modeling and simulation approaches are useful tools to assess the potential outcome of different scenarios in bioequivalence studies. The aim of this study is to propose a new and improved semi-physiological model for bioequivalence trial simulations and apply it for all BCS (Biopharmaceutic Classification System) drug classes with non-saturated first-pass hepatic metabolism. The semi-physiological model was developed in NONMEM VI to simulate bioequivalence trials. Parent drug and metabolite levels for both reference and test were simulated. Eight types of drugs (with high or low permeability and high or low solubility (class I to IV) and high or low intrinsic clearance) were considered in …

DrugAnalytemedia_common.quotation_subjectMetabolitePharmaceutical ScienceBioequivalencePharmacologychemistry.chemical_compoundFirst pass effectPharmacokineticsHumansComputer SimulationPharmacokineticsTissue Distributionmedia_commonDose-Response Relationship DrugChemistryNONMEMLiverNonlinear DynamicsPharmaceutical PreparationsTherapeutic EquivalencyArea Under CurveData Interpretation StatisticalDrug metabolismAlgorithmsEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct